Hepatitis B virus infection affects over 250 million chronic carriers, causing more than
800,000 deaths annually, although a safe and effective vaccine is available. Currently used …

Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B
(CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with …

The experts of Taiwan Association for the Study of Liver (TASL) have actively participated
and led the guidelines on hepatitis B virus (HBV) management by Asian Pacific Association …

Oral nucleoside/nucleotide analogues (NAs) are currently the backbone of chronic hepatitis
B (CHB) infection treatment. They are generally well-tolerated by patients and safe to use …

Background/Aims Studies have shown that nucleos (t) ide analogue (NA) treatment can
reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but …

This study aims to assess the nephrotoxicity and efficacy of tenofovir disoproxil fumarate
(tenofovir), telbivudine and entecavir. A retrospective study of 587 patients with chronic …

Renal fibrosis yields decreased renal function and is a potent contributor to chronic kidney
disease (CKD). Telbivudine (LdT) is an anti–hepatitis B virus (HBV) drug that has been …

Background To assess the potential effects of telbivudine (LdT) and entecavir (ETV) on renal
function in patients with chronic hepatitis B (CHB), we performed a meta-analysis of the …

The goal of chronic hepatitis B (CHB) treatment is to achieve seroclearance of HBsAg.
Nucleos (t) ide analogues (NA s) are one of the first‐line treatments for CHB. NA s produce a …

This study aimed to assess the renal function in chronic hepatitis B (CHB) patients who
received nucleos (t) ide analogues (NAs) therapy using estimated glomerular filtration rate …